Accéder au contenu
Merck
Toutes les photos(1)

Documents

Y0000626

Ketorolac trometamol for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Ketorolac tris salt, (±)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid tris salt, Toradol

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C15H13NO3 · C4H11NO3
Numéro CAS:
74103-07-4
Poids moléculaire :
376.40
Numéro MDL:
MFCD00887595
Code UNSPSC :
41116107
ID de substance PubChem :
329831061
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

ketorolac

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

NC(CO)(CO)CO.OC(=O)C1CCn2c1ccc2C(=O)c3ccccc3

InChI

1S/C15H13NO3.C4H11NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13;5-4(1-6,2-7)3-8/h1-7,11H,8-9H2,(H,18,19);6-8H,1-3,5H2

Clé InChI

BWHLPLXXIDYSNW-UHFFFAOYSA-N

Informations sur le gène

human ... PTGS1(5742) , PTGS2(5743)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ketorolac trometamol for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

PHR1140

Ketorolac Tromethamine, Pharmaceutical Secondary Standard; Certified Reference Material

Y0000486

Ketorolac trometamol, European Pharmacopoeia (EP) Reference Standard

1356665

Ketorolac Tromethamine, United States Pharmacopeia (USP) Reference Standard

1356326

Ketorolac Related Compound B, United States Pharmacopeia (USP) Reference Standard

1356315

Ketorolac Related Compound A, United States Pharmacopeia (USP) Reference Standard

1356337

Ketorolac Related Compound C, United States Pharmacopeia (USP) Reference Standard

1356348

Ketorolac Related Compound D, United States Pharmacopeia (USP) Reference Standard

PHR2493

Ketorolac Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2494

Ketorolac Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Skull and crossbones
GHS06

Mention d'avertissement

Danger

Mentions de danger

H301,H315,H319,H335

Classification des risques

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organes cibles

Respiratory system

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Giuseppina Magni et al.
Anesthesia and analgesia, 116(2), 443-447 (2013-01-11)
Ketorolac tromethamine (ketorolac) is a nonsedating drug with potent analgesic and moderate anti-inflammatory activity, which does not increase the sedation level. The safety of ketorolac with respect to risk of bleeding has been demonstrated in large numbers of patients undergoing
Stephen J Kim et al.
Archives of ophthalmology (Chicago, Ill. : 1960), 130(4), 456-460 (2012-04-12)
To investigate the adverse ocular effects of intravitreal ketorolac (4 mg) in patients with chronic uveitis and complications of chronic inflammation (macular edema). We conducted a prospective phase 1 clinical trial involving 10 eyes of 10 adult patients with chronic
Michel Weber et al.
Acta ophthalmologica, 91(1), e15-e21 (2012-09-14)
To determine whether indomethacin 0.1% eye drops are at least as effective as ketorolac 0.5% eye drops in treating ocular inflammation following cataract surgery. Prospective, multicenter, investigator-masked, parallel-group, randomized, active-controlled clinical trial. Cataract patients were randomized in a 1:1 ratio
Georgios Mylonas et al.
American journal of ophthalmology, 155(2), 253-259 (2012-10-06)
To investigate intraretinal changes after successful cataract surgery in patients with previous pars plana vitrectomy (PPV) and indocyanine green-assisted peeling of epiretinal membrane and internal limiting membrane (ILM). Prospective nonrandomized controlled clinical study. Twenty eyes of 20 patients with cataract
V R Sinha et al.
Expert opinion on drug delivery, 6(9), 961-975 (2009-08-12)
Ketorolac tromethamine (KT) is a non-steroidal anti-inflammatory drug that belongs to the class of heteroaryl acetic acid derivatives. It is a non-selective cyclooxygenase (COX) inhibitor, being marketed in the racemate form. Most of its analgesic and COX inhibitory activity is
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique